ClinicalTrials.gg
RecruitingNCT06545708EpiMUSUpdated Dec 9, 2024

Music Perception in SeLECTs

An observational study in Rolandic Epilepsy, sponsored by Hospices Civils de Lyon. Recruiting at 2 sites in France. Open to participants aged 5 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
5 Years to 14 Years
Sex
All
01

Study summary

Self-limited epilepsy with centrotemporal spikes (SeLECTS) is the most frequent epilepsy syndrome in children between the ages of 4 and 13 years. SeLECTS is associated in 15 to 30% of patients with specific cognitive deficits, including in particular disorders in language, visuo-spatial memory, declarative memory, and attention. SeLECTS has the potential to evolve into Landau-Kleffner syndrome, the most extreme form of SeLECTS including symptoms of auditory agnosia and aphasia, with potential risks of persistent neuropsychological impairments. In a recent study in adults who had suffered Landau-Kleffner syndrome during childhood, the investigators have shown that these patients, in addition to their known deficit in verbal short-term memory, also exhibit persistent musical difficulties during adulthood, with in particular deficit in melody and rhythm short-term memory.

In the present project, the investigators intend to enlarge the understanding of cognitive deficits generated by SeLECTS in children by investigating the integrity of music perception, both for melody and rhythm. To date, data about music perception in children with epilepsy are scarce and we do not know how distinct components of melody and rhythm perception and memory may be altered.

Read the detailed description

Self-limited epilepsy with centrotemporal spikes (SeLECTS) is the most frequent epilepsy syndrome in children between the ages of 4 and 13 years. The defining electroclinical feature of SeLECTS is the presence of centrotemporal spikes on EEG between seizures. SeLECTS is associated with specific cognitive deficits in 15 to 30% of patients, including disorders in language, visuo-spatial memory, explicit memory, and attention. The centrotemporal spikes are activated in sleep and, in rare cases, the condition has the potential to evolve into an Epileptic Encephalopathy with spike- and- wave activation in sleep (EE-SWAS), including Landau-Kleffner syndrome. The latest is characterized by symptoms of auditory agnosia and aphasia, with potential risks of persistent neuropsychological impairments. In a previous study, it has been shown that these patients also exhibit persistent musical difficulties.

In the present project, the investigators intend to enlarge the understanding of cognitive deficits generated by SeLECTS in children by analyzing the integrity of music perception, both for melody and rhythm, as well as testing the potential of a musical intervention for auditory and cognitive training in children suffering from SeLECTS.

The current research plan is to explore music perception in this specific epilepsy syndrome, with behavioral testing (Experiment 1) and neuroimaging using functional Near-Infrared Spectroscopy (fNIRS) (Experiment 2), and on the long run, informed by this exploration and previous studies, the design of a musical therapeutic intervention is envisioned in order to evaluate the impact of this program on music perception, language, and memory.

02

Conditions studied

  • Rolandic Epilepsy

Keywords

  • Epilepsy
  • music
  • childhood
  • neurology
  • rhythm
  • pitch
  • language
03

In context

Epilepsy, Rolandic

23 studies on the registry are indexed under Epilepsy, Rolandic; 3 are open to participants now.

Browse Epilepsy, Rolandic studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participants will be recruited from a population of 5 to 14 years of age. 50 healthy control participants will be recruited by posting flyers and/or by electronic message, and 50 epileptic patients will be recruited within the HFME child epileptology department (HCL). Their inclusion will be made at the CRNL or HFME by one of the study investigators.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject aged between 5 and 14 years old
  • Non-opposition of parents or guardians for the child's participation in the study
  • No major cognitive impairment and ability to understand and apply instructions
  • Subject affiliated to a social security scheme
  • Subject motivated to participate in the project
  • Proficiency with the French language

For the group of control participants:

  • Without neurological or psychiatric history

For the group of participants with seizure disorder:

  • No neurological (except EPCT) or psychiatric history
  • Diagnosis of self-limited epilepsy with centro-temporal spikes (PTSE) by a qualified healthcare professional.

Exclusion criteria

Exclusion Criteria:

  • Major cognitive impairment or inability to understand and apply instructions
  • Individuals refusing to participate in the study
  • Pregnant or breastfeeding minors
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.

    Other: Patients

  • Controls

    This group consists of healthy individuals between 5 and 14 years old, with no history of epilepsy and/or other neurodevelopmental disorders.

    Other: Patients

Interventions

  • OtherPatients

    This group consists of children and adolescents between the ages of 5 and 14, diagnosed with self-limited epilepsy with centrotemporal spikes by a medical professional (epileptologist or neurologist), and in the active phase of the disorder.

06

What researchers measure

Primary outcomes

  1. Performance obtained in melodic tasks

    Comparison between controls and patients using Bayesian ANOVAs to the percentages of correct responses obtained with melodic tasks

    Time frame: 2 Years

  2. Performance obtained in melodic tasks

    Comparison between controls and patients using Bayesian ANOVAs to response times obtained with melodic tasks;

    Time frame: 2 Years

  3. Performance obtained in rhythmic tasks

    Comparison between controls and patients using Bayesian ANOVAs to the percentages of correct responses obtained with rhythmic tasks

    Time frame: 2 Years

  4. Performance obtained in rhythmic tasks

    Comparison between controls and patients using Bayesian ANOVAs to response times obtained with rhythmic tasks.

    Time frame: 2 Years

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Aug 9, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06545708
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Nov 13, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 9, 2024

Study contacts

Maria PAPADOPOULOU, MD
Contact
maria.papadopoulou@chu-lyon.fr
04 27 85 65 78
Anne CACLIN, PhD
Contact
anne.caclin@inserm.fr
04.72.13.89.04

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion